KBO Systems

KBO SYSTEMS Investor Update • March 2026 MIT Validates Our Science. We Were Already There. We have several important updates to share, including a powerful independent endorsement from the scientific community. External Validation MIT Confirms the Science Behind KBO Last week, researchers at MIT published a study confirming that propofol, ketamine, and dexmedetomidine, three of the most widely used anesthesia drugs, all produce the same universal brain signature during unconsciousness, despite having completely different molecular mechanisms. The MIT findings were generated in animal studies. KBO is generating the human clinical data at UC Davis that brings this science into the perioperative space. This is the scientific foundation KBO has been building on. The study validates our most important claims directly. 🧠 Drug-agnostic monitoring is scientifically sound The same EEG-based signal can reliably track unconsciousness regardless of which drug is being used. This is exactly what KBO's platform is designed to do, and exactly what Medtronic BIS and Masimo SedLine cannot. 🔊 Auditory stimulation is a validated monitoring tool MIT researchers measured each subject's brain state by analyzing responses to auditory tones. This is the same methodology underlying KBO's Auditory Evoked Potential (AEP) technology. 📡 EEG is the right modality MIT researchers are now actively developing their own EEG-based monitoring system based on these findings, further confirming that the field is moving in the direction KBO has already staked out and is patent-pending. ⚠️ Over-sedation directly harms vulnerable patients MIT confirms that over-sedation worsens dementia and neuropsychiatric conditions in surgical patients. KBO's pre-operative cognitive screening, depth monitoring, and delirium detection are precisely designed to protect this at-risk population. MIT confirmed the risk. KBO is building the solution. Read the full MIT article → Company Milestones KBO Progress Update • Q1 2026 🔒 Intellectual Property Master Non-Provisional Patent Filed Filed January 2026. Our foundational IP encompasses the core technology validated by the MIT research, including our drug-agnostic EEG monitoring approach, algorithms, and our Auditory Evoked Potential (AEP) methodology. 🏥 Clinical Development Active Clinical Testing at UC Davis Clinical enrollment is ongoing. We are collecting a minimum of one new patient per week, steadily building the proprietary dataset that will power our 510(k) submission. 📄 Scientific Publications First Peer-Reviewed Publication in Progress We are actively co-authoring our first peer-reviewed journal article with UC Davis researchers covering KBO's overall platform technology, including our auditory evoked potential approach. We expect to submit for publication later this year. 💰 Reimbursement Strategy Insurance Reimbursement Pathway on Track KBO is building toward the only insurance reimbursement pathway in perioperative brain monitoring. Upon FDA clearance, our platform is designed to generate billable revenue for clinical sites using existing CPT codes, converting monitoring from a cost center into a net revenue-positive workflow. Why this matters for your investment. The science is being confirmed publicly. Our IP is protected. Our clinical evidence is being built. We are on track and building momentum. Kevin Goehl Founder & CEO, KBO Systems kbosystems.com Confidential • KBO Systems, Inc. • For Accredited Investors Only